Alembic Pharmaceuticals logo

Alembic Pharmaceuticals results

NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap

Last close ₹760.10down ₹21.20 (2.71%)BSE ₹758.75

Share price at the NSE close on 23 Oct 2026. Previous close ₹781.30.

52-week range of traded prices to 23 Oct 2026
₹635.80Low, 23 Mar 2026₹998.00High, 4 Nov 2025
Market cap
₹14,941 Cr430th largest listed
P/E
21.6
P/B
2.6
Dividend yield
1.58%
ROE
12.7%
ROCE
11.8%
Debt to equity
0.24
Volume, NSE
1,20,84752.2% delivered

Q1 results, quarter to Jun 2026

Consolidated: the company and its subsidiaries together. ₹ crore.Alembic Pharmaceuticals annual results and balance sheet

Revenue
₹2,150 Cr+25.7% on a year ago · +16.3% on the quarter before
Operating profit
₹332 Cr+18.0% on a year ago · +45.6% on the quarter before
Net profit
₹172 Cr+12.2% on a year ago · −14.5% on the quarter before
Earnings per share
₹8.80+12.1% on a year ago · −14.6% on the quarter before
Operating margin
15.4%
Net margin
8.0%

From revenue to net profit, ₹ crore

  1. Revenue2,150
  2. Materials and goods−620
  3. Employee costs−474
  4. Other expenses−724
  5. Operating profit332
  6. Depreciation−98
  7. Other income+15
  8. Finance costs−28
  9. Profit before tax221
  10. Tax−50
  11. Joint ventures+0.4
  12. Net profit172

Alembic Pharmaceuticals results by quarter

Consolidated: the company and its subsidiaries together. Latest quarter to Jun 2026. Results for the quarter to Sep 2026 are due by 14 Nov 2026, 45 days after it ends.Results filings and date

Revenue and net profit by quarter, ₹ crore

  • Revenue
  • Net profit

Operating and net margin by quarter, per cent

  • Operating margin
  • Net margin
₹ croreSep 2021Q2Filed 11 NovDec 2021Q3Filed 10 FebMar 2022Q4Filed 4 MayJun 2022Q1Filed 5 AugSep 2022Q2Filed 11 NovDec 2022Q3Filed 2 FebMar 2023Q4Filed 6 MayJun 2023Q1Filed 4 AugSep 2023Q2Filed 9 NovDec 2023Q3Filed 6 FebMar 2024Q4Filed 10 MayJun 2024Q1Filed 9 AugSep 2024Q2Filed 7 NovDec 2024Q3Filed 3 FebMar 2025Q4Filed 10 JunJun 2025Q1Filed 5 AugSep 2025Q2Filed 5 NovDec 2025Q3Filed 5 FebMar 2026Q4Filed 15 MayJun 2026Q1Filed 4 Aug
Revenue from operations1,2921,2721,4161,2621,4751,5091,4061,4861,5951,6311,5171,5621,6481,6931,7701,7111,9101,8761,8482,150
1,0351,0161,2561,2471,2421,2601,1941,2871,3871,3641,2571,3251,4091,4331,4981,4291,5941,5831,6201,818
Materials and goods bought333343386378443455432414461461379394429440531407516529532620
Employee costs293273277290290291298348347349402380391398394423438433439474
Other expenses409401593579509514464526578554476551588595574599641621649724
Operating profit before depreciation25725616015233249212199208266260237239260272281316294228332
Operating margin19.9%20.1%11.3%1.2%15.8%16.5%15.1%13.4%13.1%16.3%17.1%15.2%14.5%15.4%15.4%16.4%16.5%15.6%12.3%15.4%
Depreciation and amortisation55561236768677466686969697170697476808998
Other income21101001121034217101477162615
Finance costs547912151414161511131922252424232328
Profit before one-off items and tax20019741−60153168125130135185183157167177193191222206142221
One-off items000000000000130000−42−250
Profit before tax20019741−60153168125130135185183157180177193191222163118221
4032−2−11833−369−24522274035364030−8350
Tax rate19.7%16.5%−4.3%–11.7%19.4%−29.2%7.1%−1.4%2.2%2.5%14.4%15.2%22.6%18.3%19.1%18.0%18.1%−70.5%22.4%
Share of profit of joint ventures and associates34−12−7−2−14−80−100010−101−210
16416830−66133122153121137180178135153138157154184132202172
Other comprehensive income400563−1−111−12−3126158122
Total comprehensive income16816831−61140125151120137181167131154140162154188140213175
Net margin12.7%13.2%2.1%−5.2%9.0%8.1%10.9%8.1%8.6%11.1%11.7%8.6%9.3%8.1%8.9%9.0%9.6%7.0%10.9%8.0%
Net margin without joint ventures and associates12.4%12.9%3.0%−4.6%9.2%9.0%11.5%8.1%8.6%11.1%11.8%8.6%9.2%8.1%8.9%9.0%9.5%7.1%10.8%8.0%
Earnings per share₹8.61₹8.98₹1.80−₹3.35₹6.78₹6.20₹7.76₹6.14₹6.95₹9.18₹9.07₹6.85₹7.79₹7.01₹7.98₹7.85₹9.40₹6.76₹10.31₹8.80
Earnings per share in rupees, restated for later splits and bonuses.

Filed results, as an XML file each

16 earlier filings